

Preliminary Amendment

Applicant(s): STEER et al.

Serial No. 10/549,867

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITYRECEIVED
CENTRAL FAX CENTER

Page 2 of 9

DEC 13 2007

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

1. (Currently amended) A method of promoting viability of a transplant cell population comprising contacting the transplant cell population with an effective amount of a compound selected from the group consisting of a hydrophilic bile ursodeoxycholic acid, a salt thereof, an analog thereof, and a combination thereof.
2. (Original) The method of claim 1 wherein cells of the transplant cell population are differentiated cells.
3. (Original) The method of claim 1 wherein cells of the transplant cell population are precursor cells.
4. (Original) The method of claim 1 wherein the contacting occurs *in vitro*.
5. (Original) The method of claim 1 wherein the contacting occurs *in vivo*.
6. (Original) The method of claim 5 wherein the contacting occurs in a donor of the transplant cell population.
7. (Currently amended) The method of claim 1 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population with the compound *in vitro* prior to transplanting the transplant cell population in a subject.
8. (Original) The method of claim 7 wherein the subject is a human.

Preliminary Amendment

Page 3 of 9

Applicant(s): STEER et al.

Serial No. 10/549,867

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITY

9. (Original) The method of claim 7 further comprising treating the subject with the compound.
10. (Original) The method of claim 9 wherein treating the subject with the compound comprises administering the compound to the subject prior to transplanting the transplant cell population in the subject.
11. (Currently amended) The method of claim 10 wherein treating the subject with the compound further comprises administering the compound to the subject after transplanting the transplant cell population in the subject.
12. (Original) The method of claim 9 wherein treating the subject with the compound comprises administering the compound to the subject after transplanting the transplant cell population in the subject.
13. (Original) The method of claim 9 wherein treating the subject comprises treating the subject parenterally with the compound.
14. (Original) The method of claim 9 wherein treating the subject comprises treating the subject orally with the compound.
15. (Original) The method of claim 1 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population in combination with a pharmaceutically acceptable carrier.
16. (Original) The method of claim 1 wherein the cells of the transplant cell population comprise autologous cells, heterologous cells, or xenologous cells.

Preliminary Amendment

Page 4 of 9

Applicant(s): STEER et al.

Serial No. 10/549,867

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITY

17. (Original) The method of claim 1 wherein the cells of the transplant cell population comprises at least a portion of autologous tissue, heterologous tissue, or xenologous tissue.
18. (Original) The method of claim 1 wherein the transplant cell population is an organ.
19. (Original) The method of claim 18 wherein the organ is a liver, a kidney, a heart, a lung, or a pancreas.
- 20-22. (Cancel)
23. (Withdrawn/currently amended) A method of promoting the viability of a cell transplant population in the treatment of ~~for treating~~ a subject having Parkinson's disease, the method comprising:
- contacting ~~[[a]]~~ the transplant cell population *in vitro* with an effective amount of a compound selected from the group consisting of ursodeoxycholic acid, a salt thereof, an analog thereof, and a combination thereof to promote viability of the transplant cell population; and
- transplanting the transplant cell population into ~~[[a]]~~ the subject.
24. (Withdrawn) The method of claim 23 wherein the ursodeoxycholic acid analog includes a conjugated derivative.
25. (Withdrawn) The method of claim 24 wherein the conjugated derivative is tauroursodeoxycholic acid.
26. (Withdrawn) The method of claim 23 wherein the subject is a human.
27. (Withdrawn) The method of claim 23 wherein the cells are differentiated cells.
28. (Withdrawn) The method of claim 23 wherein the cells are precursor cells.

Preliminary Amendment

Page 5 of 9

Applicant(s): STEER et al.

Serial No. 10/549,867

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITY

29. (Withdrawn/currently amended) The method of claim [[23]] 27 wherein the ~~contacting~~ occurs *in vitro* cells are neuronal cells.

30. (Withdrawn/currently amended) The method of claim [[23]] 28 wherein the ~~contacting~~ occurs *in vivo* cells are neuronal cells.

31-32. (Cancel)

33. (Withdrawn/currently amended) The method of claim [[32]] 23 further comprising treating the subject with the compound.

34. (Withdrawn) The method of claim 33 wherein treating the subject with the compound comprises administering the compound to the subject prior to transplanting the cells in the subject.

35. (Withdrawn/currently amended) The method of claim 34 wherein treating the subject with the compound further comprises administering the comprising to the subject after transplanting the cells in the subject.

36. (Withdrawn) The method of claim 33 wherein treating the subject with the compound comprises administering the compound to the subject after transplanting the cells in the subject.

37. (Withdrawn/currently amended) The method of claim [[23]] 33 wherein treating the subject comprises treating the subject parenterally with the compound.

38. (Withdrawn/currently amended) The method of claim [[23]] 33 wherein treating the subject comprises treating the subject orally with the compound.

Preliminary Amendment

Page 6 of 9

Applicant(s): STEER et al.

Serial No. 10/549,867

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITY

39. (Withdrawn) The method of claim 23 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population in combination with a pharmaceutically acceptable carrier.
40. (Withdrawn) The method of claim 23 wherein the cells comprise autologous cells, heterologous cells, or xenologous cells.
41. (Withdrawn/currently amended) The method of claim 23 wherein the cells comprise[[s]] ~~at least a portion of autologous tissue, heterologous tissue, or xenologous tissue~~ neuronal cells.
42. (Withdrawn/currently amended) A method of promoting viability of a transplant cell population the method comprising:
treating a donor of a transplant cell population with a compound selected from the group consisting of ursodeoxycholic ~~a hydrophilic bile~~ acid, a salt thereof, an analog thereof, and a combination thereof.
43. (Cancel)
44. (Withdrawn/currently amended) The method of claim 42 wherein the ~~hydrophilic bile~~ ursodeoxycholic acid comprises tauroursodeoxycholic acid, ~~and treating the donor comprises treating the donor with the tauroursodeoxycholic acid.~~
45. (Withdrawn) The method of claim 42 wherein the donor of the transplant cell population is living.
46. (Withdrawn) The method of claim 42 wherein treating the donor comprises treating the donor with the compound before removal of the transplant cell population from the donor.

Preliminary Amendment

Page 7 of 9

Applicant(s): STEER et al.

Serial No. 10/549,867

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITY

47. (Withdrawn) The method of claim 42 wherein treating the donor comprises treating the donor with the compound during removal of the transplant cell population from the donor.

48. (Withdrawn/currently amended) The method of claim 42 further comprising wherein treating the donor comprises treating the donor with the compound after removal of the transplant cell population from the donor.

49. (Withdrawn) The method of claim 42 wherein the transplant cell population is at least a portion of an organ of the donor.

50. (Withdrawn) The method of claim 49 wherein the at least a portion of the organ is the entire organ of the donor.

51. (Withdrawn) The method of claim 42 wherein treating the donor comprises treating the donor parenterally with the compound.

52. (Withdrawn) The method of claim 42 wherein treating the donor comprises treating the donor orally with the compound.

53. (Withdrawn) The method of claim 42 wherein treating the donor with the compound comprises contacting the transplant cell population in combination with a pharmaceutically acceptable carrier.

54. (Withdrawn/currently amended) A method, comprising:
treating a subject for a transplant cell population with a compound selected from the group consisting of a hydrophilic bile ursodeoxycholic acid, a salt thereof, an analog thereof, and a combination thereof.

55-65. (Cancel)

Preliminary Amendment

Page 8 of 9

Applicant(s): STEER et al.

Serial No. 10/549,867

Filed: September 22, 2005

For: METHODS OF PROMOTING CELL VIABILITY

66. (New) The method of claim 1 wherein the ursodeoxycholic acid analog includes a conjugated derivative.
67. (New) The method of claim 66 wherein the conjugated derivative is tauroursodeoxycholic acid.
68. (New) The method of claim 1 wherein the cells are neuronal cells.
69. (New) The method of claim 68 wherein the cells are transplanted into a subject with Parkinson's disease.
70. (New) The method of claim 68 wherein the survival of dopamine neurons in the transplanted neuronal cell population is enhanced.
71. (New) The method of claim 68 wherein apoptosis of dopamine neurons in the transplanted cell population is reduced.
72. (New) The method of claim 1 further comprising transplanting the transplant cell population into a subject.
73. (New) The method of claim 72 further comprising administering an immunosuppressive pharmaceutical to the subject.
75. (New) The method of claim 23 further comprising administering an immunosuppressive pharmaceutical to the subject.